financetom
Business
financetom
/
Business
/
Canopy Growth CEO Says German Cannabis Market Has 'Ability To Grow 10x' Following Legalization
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canopy Growth CEO Says German Cannabis Market Has 'Ability To Grow 10x' Following Legalization
Mar 26, 2024 12:53 PM

The German government partially legalized cannabis last week, and Canopy Growth Corporation ( CGC ) shares lit up. Canopy Growth ( CGC ) CEO David Klein joined BNN Bloomberg on Friday to discuss what the legislation means for the company.

Growth Opportunities: Klein sees Germany's cannabis market growing from its current value of just under $500 million to over $2.5 billion in the next two years.

"We think that the market has the ability to grow 10x over the next several years. Most of the revenue is going to come through the medical channel, which is where you will see the commercial benefit for Canopy," Klein predicted. 

Canopy released a statement on Friday celebrating the legalization of cannabis in Germany and expressing its desire to expand its position as a top-three cannabis brand in the country. 

“We are thrilled to be able to continue serving the medical community by delivering high-quality cannabis products that meet patient needs and we look forward to increasing our already leading presence in the German medical cannabis market,” said Tara Rozalowsky, chief growth officer and president, International, Canopy Growth ( CGC ).

Klein expressed similar views in the Bloomberg interview and noted that he sees the new German legislation opening a door to increased profitability for Canopy Growth ( CGC ).

Related News: WallStreetBets Is Buzzing About Digital World Stock Ahead Of Trump Media’s First Trade Under DJT Ticker

"Over the past few years, we've reset our business so that we could profitably take advantage of these sort of opportunities as we get regulatory unlocks, whether it’s in Germany or the U.S. and maybe even some progress in Canada," Klein said.

Retail Chimes In: Redditors in the r/weedstocks subreddit shared differing opinions on Canopy's prospects in Germany. 

"CGC is competing with companies it failed to compete with in Canada. Why would it be any different in Germany? It makes no sense," posted u/LectureAgreeable923.

"Here's hoping the German market develops in a robust way like the Australian medical market," posted a more hopeful u/corinalas. 

CGC Price Action: According to Benzinga Pro, Canopy Growth ( CGC ) shares were up 23.1% at $7.62 at the time of publication Tuesday. 

Image: asdqwejkl from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rocket Lab USA Says It Delivered Second Spacecraft for Varda
Rocket Lab USA Says It Delivered Second Spacecraft for Varda
Dec 17, 2024
09:02 AM EST, 12/17/2024 (MT Newswires) -- Rocket Lab USA ( RKLB ) said Tuesday it delivered a second spacecraft to Vandenberg Space Force Base and completed production of a third for Varda Space Industries under a four-spacecraft contract supporting in-orbit pharmaceutical manufacturing and reentry operations. The company said the Pioneer spacecraft, built by Rocket Lab, supports Varda's capsule, which...
Synopsys, SiMa.ai team up to speed development of AI chips for cars
Synopsys, SiMa.ai team up to speed development of AI chips for cars
Dec 17, 2024
Dec 17 (Reuters) - Silicon Valley-based Synopsys ( SNPS ) and startup firm SiMa.ai announced on Tuesday a partnership aimed at accelerating the development of new artificial intelligence chips for automakers and their suppliers. Synopsys ( SNPS ), among leading manufacturers of chip-design software, will collaborate with SiMa.ai, a company that has designed energy-efficient hardware and software capable of handling...
New HIV prevention drug could reach poorest countries by 2025, says health official
New HIV prevention drug could reach poorest countries by 2025, says health official
Dec 17, 2024
LONDON, Dec 17 (Reuters) - A new long-acting preventive HIV drug could reach the world's poorest countries by the end of 2025 or early 2026, a global health official told Reuters on Tuesday. The ambition is to start deliveries of Gilead Sciences' ( GILD ) lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund...
Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer
Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024
09:01 AM EST, 12/17/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday that its antibody-drug conjugate Trodelvy was granted US Food and Drug Administration breakthrough therapy designation for the treatment of adults with extensive-stage small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy. The designation, which speeds up the FDA approval process, was based...
Copyright 2023-2026 - www.financetom.com All Rights Reserved